$TCBP Announces Grant of European #Patent for Targeting of Microbial, #Oncological, and Viral Indications using Modified Gamma Delta T Cells
https://t.co/jXHHjENZzd
@123Kiki@Unluckiest2083 the stock closed below $1 for 30 days as part a short and distort campaign that was placed against the company last fall. This delisting is a result of that.
@Unluckiest2083 This attack on company stock price was a direct result of fraud. Subsequently, we put in front of Nasdaq panel a very strong case showing our commitment and track record of compliance. They moved to delist us.
@Unluckiest2083 $TCBP was part of a "short and distort" campaign. We made a concerted effort but the stock never recovered and "closed", not "traded" below $1 for 30 straight days. We chose not to split the stock because we had several key announcements and hoped to avoid hurting investors.
$TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
The company is expected to reduce core operational burn by 55% when compared to 2024
https://t.co/Nhg7ODF5e2
@hyjr2@TCBioPharm The conference was well attended and we held individual meetings with perspective investors on-site. We are also speaking with relevant investors regularly.
$TCBP shareholders,
As stated in our 6k, the Company intends to appeal the notice to the Nasdaq Panel. This follows the same process we previously followed when receiving these notices from Nasdaq when we were in deficiency status.